^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:Gastric Cancer
    Drug:Tevimbra (tislelizumab-jsgr) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO Asia 2023
    Title:

    139MO - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

    Published date:
    11/27/2023
    Excerpt:
    Adults with previously untreated, HER2-negative, locally advanced, unresectable, or metastatic GC/GEJC...were randomized (1:1) to receive TIS 200 mg...In the ITT population, TIS + chemo showed statistically significant and clinically meaningful improvement in OS vs PBO + chemo and was well tolerated. These data support the TIS + chemo combination as a potential 1L treatment option for pts with advanced GC/GEJC.
    Secondary therapy:
    Chemotherapy
    Trial ID:
    RATIONALE 305
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

    Excerpt:
    ...Pathologically (histologically or cytologically) confirmed diagnosis of either inoperable, locally advanced or metastatic gastric/GEJ adenocarcinoma that is HER2/neu negative or inoperable, locally advanced or metastatic ESCC....
    Trial ID:
    BGB-A317-205
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

    Excerpt:
    ...Pathological immunohistochemistry or FISH detection of gastric cancer tissue indicates negative Her-2; 3....
    Trial ID:
    NCT06034964
    More C2 evidence